New BOFAS Conference Page New BOFAS Conference Page Now Live! 30 June 2023 Visit here: https://www.bofas.org.uk/annual-meeting/ Read more
BOFAS 2023 Video Recap BOFAS 2023 Video Recap Now Live for Members who attended the conference 19 May 2023 If you are a BOFAS member who attended the 2023 annual congress, you can now access the full video recap of the conference here. Read more
BOFAS 2024 - Belfast BOFAS 2024 - Belfast 6th to 8th March 2024 15 March 2023 BOFAS 2024 will be held in Belfast from 6th to 8th of March Read more
20Apr2026 BOFAS Diabetic Foot Principles Course 20/04/2026 Read more BOFAS Diabetic Foot Principles Course 20th April 2026, Delta by Marriott Hotel, Milton Keynes £150.00 Read more
29Apr2026 BOFAS Trauma Course 29/04/2026 Read more BOFAS Trauma Course 29th April 2026, Bristol £150 Read more
15May2026 BOFAS Allied Health Professionals Course 15/05/2026 Read more BOFAS Allied Health Professionals Course 15th May 2026, Bournemouth Read more
2Jul2026 BOFAS Basics & Advanced Arthroscopy Skills Course 02/07/2026 Read more BOFAS Basics & Advanced Arthroscopy Skills Course 2nd-3rd July 2026, Solihull Read more
1Oct2026 BOFAS Principles Course 01/10/2026 Read more BOFAS Principles Course 1st-2nd October 2026, Glasgow £325.00 Read more
6May2026 Nordic Foot & Ankle Congress 06/05/2026 - 07/05/2026 Read more Nordic Foot & Ankle Congress BOFAS Members have been invited to the Nordic Foot & Ankle Congress May 6/7 2026 in Oslo. Read more
Karan Malhotra / 14 February 2021 / Categories: Abstracts, 2021, Poster DVT and Achilles tendon rupture - a better pill to swallow? G. Scott, A. Biggs, A. Carne, M. Rogers, M. Solan Background: The BOFAS Guidance regards Achilles rupture patients as particularly high risk for VTE. Many hospitals use 6-weeks of low molecular weight heparin (LMWH) injections which are unpleasant for patients and result in reduced compliance. An extended course of prophylaxis is advised following hip and knee arthroplasty, however Novel Oral Anti-Coagulant (NOAC) tablets are licensed. We offered Rivaroxaban to our Achilles patients as an alternative. Since this is “off-license”, we developed an information sheet and consent form. In this study we compared VTE prophylaxis outcomes in our Achilles rupture patients. Methods: We retrospectively reviewed patients diagnosed during three different periods between 2010 and 2019. During the first patients were treated in any fracture clinic. Chemical prophylaxis was not always prescribed. In the second period patients were triaged to a Foot & Ankle clinic. VTE prophylaxis was universal but not standardised. The third period saw patients managed by one F&A surgeon using the Rivaroxaban protocol. Thromboembolic event or significant bleeding within 3 months of treatment were recorded outcomes. Results: Two hundred and thirty patients with Achilles tendon rupture were identified. Thirty-one were excluded because they took anticoagulants already or had a DVT on initial USS. There were no secondary bleeding episodes or fatal PEs. Forty patients had no prophylaxis and 7.5% of these developed a symptomatic DVT or PE. Of the 80 patients managed with LMWH, 6.25% suffered a thromboembolic event. A total of 79 patients were given Rivaroxaban and zero suffered a DVT or PE. Conclusion: Numbers here are small, but suggests Rivaroxaban is an appropriate alternative to LMWH. Poor compliance due to pain and bruising from injections isn't relevant with a tablet that also doesn't require any patient/family education. Rivaroxaban has led to improved VTE rates for patients with Achilles tendon rupture in our hospital with no complications. Print 7414 Tags: AchillesVTE Documents to download P1 G Scott BOFAS Poster Submission(.pdf, 140.93 KB) - 1963 download(s)